Table 3.

Recently Published Studies on Keratoplasty Indications

	New Zealand			China				Scotland			Canada				Hungary
	n = 2,253			n = 5,316				n = 921			n = 3,571				n = 402
	Cunningham et al. [8]			Xie et al. [11]				Ting et al. [6]			Sheldon et al. [5]				Módis et al. [4]
	2000-2009			1996-2007				2001-2010			1995-2005				2006-2009
Keratoconus	938	41,6%		674	12,7%			264	28,7%		592		16,6%		60	14,9%
PBK/ABK	315	14,0%		353	6,6%			88	9,6%		790		22,1%		116	28,9%
Fuchs´ Distrophy	187	8,3%		30	0,6%			191	20,7%		384		10,8%		9	2,2%
Regraft	391	17,4%		246	4,6%			177	19,2%		755		21,1%		74	18,4%
Keratitis	180	8,0%		2387	44,9%			106	11,5%		294		8,2%		22	5,5%
Stromal opacities^	94	4,2%		1195	22,5%			21	2,3%		573		16,0%		74	18,4%
Others	148	6,6%		431	8%			74	8,0%		183		5,1%		47	11,7%
	United Kingdom			Iran			Germany					Australia			Colombia (Present Study)
	n = 22,779			n = 1,859			n = 1,200					n=22,898			n = 402
	Keenan et al. [7]			Zare et al. [9]			Wang et al. [10]					Williams et al. [12]			V. Galvis et al.
	1999-2009			2004-2009			2001-2010					1985-2011			2004-2011
Keratoconus	5469		24,0%	714		38,4%	306			25,5%		6789		29,6%	51		12,7%
PBK/ABK	3597		15,8%	218		11,7%	175			14,6%		4478		19,6%	139		34,6%
Fuchs´ Distrophy	4434		19,5%	15		0,8%	254			21,2%		2790		12,2%	30		7,5%
Regraft	3318		14,6%	197		10,6%	84			7,0%		4650		20,3%	31		7,7%
Keratitis	1885		8,3%	188		10,1%	156			13,0%		1254		5,5%	58		14,4%
Stromal opacities^	1437		6,3%	297		16,0%	198			16,5%		1531		6,7%	63		15,7%
Others	2639		11,6%	230		12,4%	27			2,3%		1406		6,1%	30		7,5%